The increasing elderly population globally, coupled with the rising prevalence of chronic diseases, is a significant driver of growth in the market. As people age, they are more prone to conditions such as osteoarthritis, cardiovascular diseases, and dental issues which often require the use of bioimplants for treatment.
For instance, as per the National Institute of Health (NIH), the prevalence of chronic diseases in the geriatric population in the U.S. is high, with almost 90% of the population having at least one chronic disease. The most common chronic diseases in the geriatric population include hypertension, arthritis, diabetes, heart disease, and cancer.
Bioimplants offer a range of benefits, including improved mobility, reduced pain, and enhanced quality of life for these patients.
Further, with advancements in technology and materials, bioimplants have become increasingly effective and reliable, further fueling their demand.
Authors:
Mariam Faizullabhoy , Gauri Wani
Frequently Asked Questions (FAQ) :
Bioimplants industry size was worth USD 132 billion in 2023 and is projected showcase 8.2% CAGR from 2024 to 2032, owing to the rising prevalence of chronic diseases and conditions, such as cardiovascular diseases, orthopedic disorders, and ophthalmic diseases.
The cardiovascular implants segment in the market recorded USD 47.4 billion in 2023 and is estimated to grow between 2024 and 2032, on account of the increasing prevalence of cardiovascular diseases and significant advancements in implants technology.
North America bioimplants industry was worth USD 48.6 billion in 2023 and is predicted to grow at 7.9% CAGR between 2024 and 2032, due to the presence of robust healthcare infrastructure, advanced technological innovations, and high healthcare expenditure.
Abbott Laboratories, Arthrex inc., aap Implantate AG, Biotronik SE & Co. KG, Cochlear Ltd., DePuy Synthes (Johnson & Johnson), Edwards Lifesciences Corporation, LifeNet Health, Medtronic plc, Organogenesis Inc., Smith & Nephew plc, Stryker Corporation, and Zimmer Biomet Holdings Inc. are some of the leading bioimplants companies worldwide.